Travere Therapeutics, Inc. – NASDAQ:TVTX
Travere Therapeutics stock price today
$17.2
-0.08
-0.46%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Travere Therapeutics stock price monthly change
+76.33%
month
Travere Therapeutics stock price quarterly change
+76.33%
quarter
Travere Therapeutics stock price yearly change
+81.89%
year
Travere Therapeutics key metrics
Market Cap | 1.45B |
Enterprise value | 1.68B |
P/E | -5.17 |
EV/Sales | 10.78 |
EV/EBITDA | -7.19 |
Price/Sales | 8.56 |
Price/Book | 31.21 |
PEG ratio | 0.33 |
EPS | -5.06 |
Revenue | 183.22M |
EBITDA | -349.96M |
Income | -161.12M |
Revenue Q/Q | -27.40% |
Revenue Y/Y | -16.91% |
Profit margin | -178.34% |
Oper. margin | -311.35% |
Gross margin | -4.86% |
EBIT margin | -311.35% |
EBITDA margin | -191% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTravere Therapeutics stock price history
Travere Therapeutics stock forecast
Travere Therapeutics financial statements
Average Price Target
$22.45
Potential upside: 30.54%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 59.69M | -85.63M | -143.44% |
|---|---|---|---|
| Sep 2023 | 37.09M | 150.73M | 406.35% |
| Dec 2023 | 45.05M | -90.17M | -200.12% |
| Mar 2024 | 41.37M | -136.06M | -328.86% |
| Jun 2023 | 736429000 | 619.94M | 84.18% |
|---|---|---|---|
| Sep 2023 | 832850000 | 553.08M | 66.41% |
| Dec 2023 | 788913000 | 588.10M | 74.55% |
| Mar 2024 | 663547000 | 589.47M | 88.84% |
| Jun 2023 | -69.29M | -23.55M | 2.26M |
|---|---|---|---|
| Sep 2023 | -59.13M | 133.31M | -634K |
| Dec 2023 | -70.47M | -16.95M | 124K |
| Mar 2024 | -119.00M | 104.89M | -525K |
Travere Therapeutics alternative data
| Sep 2023 | 462 |
|---|---|
| Oct 2023 | 462 |
| Nov 2023 | 462 |
| Dec 2023 | 462 |
| Jan 2024 | 462 |
| Feb 2024 | 462 |
| Mar 2024 | 380 |
| Apr 2024 | 380 |
| May 2024 | 380 |
| Jun 2024 | 380 |
| Jul 2024 | 380 |
Travere Therapeutics other data
43.91%
-56.09%
of TVTX is owned by hedge funds
95
-58
27.99M
-44.97M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 17828 |
| Feb 2024 | 0 | 41657 |
| Apr 2024 | 0 | 54 |
| Sep 2024 | 0 | 77969 |
| Oct 2024 | 0 | 40000 |
| Nov 2024 | 0 | 12090 |
| Dec 2024 | 0 | 15000 |
| Quarter | Transcript |
|---|---|
| Q1 2024 6 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 16 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 4 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Eric M. Dube Ph.D. (1973) Pres, Chief Executive Officer & Director | $1,130,000 |
| Dr. William E. Rote Ph.D. (1963) Senior Vice President of R&D | $716,580 |
| Dr. Noah L. Rosenberg M.D. (1967) Executive Advisor | $713,930 |
Ms. Laura M. Clague CPA (1959) Chief Financial Officer | $707,620 |
| Ms. Elizabeth E. Reed (1971) Senior Vice President, Gen. Counsel & Corporation Sec. | $660,090 |
Travere Therapeutics: Cautiously Bullish Based On Improving Revenue
Mirum Pharmaceuticals: Market Overreacts To Livmarli's Phase 2 Miss
Travere Therapeutics: Tanking On Confirmatory Trial Failure For Kidney Therapy - Is There Hope?
Travere: Turbulent Journey With FILSPARI, Downgrading To Sell
Omeros: Q1 Earning Overview, Best Contrarian Biotech Play Of 2023
Calliditas: A Trailblazing Triumph In IgAN Treatment
Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race
The Filspari Paradox: Travere's Promising Drug Faces Early-Stage Challenges
Chinook: CHK-336 Trial Pause Creates Buying Opportunity, All Eyes On IgAN Readout
-
What's the price of Travere Therapeutics stock today?
One share of Travere Therapeutics stock can currently be purchased for approximately $17.2.
-
When is Travere Therapeutics's next earnings date?
Unfortunately, Travere Therapeutics's (TVTX) next earnings date is currently unknown.
-
Does Travere Therapeutics pay dividends?
No, Travere Therapeutics does not pay dividends.
-
How much money does Travere Therapeutics make?
Travere Therapeutics has a market capitalization of 1.45B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 31.5% to 145.24M US dollars.
-
What is Travere Therapeutics's stock symbol?
Travere Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TVTX".
-
What is Travere Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Travere Therapeutics?
Shares of Travere Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Travere Therapeutics's key executives?
Travere Therapeutics's management team includes the following people:
- Dr. Eric M. Dube Ph.D. Pres, Chief Executive Officer & Director(age: 52, pay: $1,130,000)
- Dr. William E. Rote Ph.D. Senior Vice President of R&D(age: 62, pay: $716,580)
- Dr. Noah L. Rosenberg M.D. Executive Advisor(age: 58, pay: $713,930)
- Ms. Laura M. Clague CPA Chief Financial Officer(age: 66, pay: $707,620)
- Ms. Elizabeth E. Reed Senior Vice President, Gen. Counsel & Corporation Sec.(age: 54, pay: $660,090)
-
How many employees does Travere Therapeutics have?
As Jul 2024, Travere Therapeutics employs 380 workers.
-
When Travere Therapeutics went public?
Travere Therapeutics, Inc. is publicly traded company for more then 12 years since IPO on 8 Nov 2012.
-
What is Travere Therapeutics's official website?
The official website for Travere Therapeutics is travere.com.
-
Where are Travere Therapeutics's headquarters?
Travere Therapeutics is headquartered at 3611 Valley Centre Drive, San Diego, CA.
-
How can i contact Travere Therapeutics?
Travere Therapeutics's mailing address is 3611 Valley Centre Drive, San Diego, CA and company can be reached via phone at +888 9697879.
-
What is Travere Therapeutics stock forecast & price target?
Based on 9 Wall Street analysts` predicted price targets for Travere Therapeutics in the last 12 months, the avarage price target is $22.45. The average price target represents a 30.54% change from the last price of $17.2.
Travere Therapeutics company profile:
Travere Therapeutics, Inc.
travere.comExchange:
NASDAQ
Full time employees:
380
Industry:
Biotechnology
Sector:
Healthcare
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
3611 Valley Centre Drive
San Diego, CA 92130
San Diego, CA 92130
CIK: 0001438533
ISIN: US89422G1076
CUSIP: 89422G107
